

Erratum

Relationship of associated secondary hyperparathyroidism to serum fibroblast growth factor-23 in end-stage renal disease: A case control study

Hamdy Sliem, Gamal Tawfik, Fadia Moustafa¹, Heba Zaki

Departments of Internal Medicine and ¹Clinical Pathology, Suez Canal University, Ismailia, Egypt

A misalignment occurred in Table 2 of the article by Sliem *et al.*, published in the April 2011, issue of IJEM.^[1]

The corrected table is printed below [Table 2].

Table 2: Correlation between FGF-23 and various parameters

Parameters	FGF-23	
	r	P-value
Age (years)	-0.2	0.09 (NS)
Hb (g / dL)	-0.6	0.03*
Serum creatinine	0.5	0.05*
Na (mEq / L)	0.07	0.6 (NS)
K (mEq) / L	0.02	0.9 (NS)
Calcium (mg / dL)	-0.7	0.01*
Phosphorus (mg / dL)	0.9	0.001*
Urea (mg/dL)	0.6	0.03*
Ferritin (ng/mL)	0.4	0.01*
PTH (pg/mL)	0.6	0.001*

PTH: Parathyroid hormone, NS: Non-significant

REFERENCE

1. Sliem H, Tawfik G, Moustafa F, Zaki H. Relationship of associated secondary hyperparathyroidism to serum fibroblast growth factor-23 in end stage renal disease: A case control study. Indian J Endocrinol Metab 2011;15:105-9.

The error is regretted.

Editor, Indian Journal of Endocrinology and Metabolism